Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Hagino H, Tanaka K, Silverman S, McClung M, et al. Osteoporos Int 2021 Mar 27. pii: 10.1007/s00198-021-05927.

Read + Share

Amedeo Smart

Independent Medical Education

Hagino H, Tanaka K, Silverman S, McClung M, et al. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int 2021 Mar 27. pii: 10.1007/s00198-021-05927.
PMID: 33772328